Mechanisms that contribute to the development of lymphoid malignancies: Roles for genetic alterations and cytokine production

Critical Reviews in Immunology

Volumn 16, Issue 1, 1996, Pages 31-57

  Levy, Laura S ^a   Bost, Kenneth L ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anti tumor immunity; lymphokines; T helper ceils

Indexed keywords

CYTOKINE;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; GENE EXPRESSION; GENE MUTATION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE TRANSFER; LYMPHOID TISSUE; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TUMOR IMMUNITY;

ANIMALS; APOPTOSIS; CELL CYCLE; CYTOKINES; DNA DAMAGE; HUMANS; IMMUNITY, CELLULAR; INTERLEUKINS; LYMPHOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION; TH1 CELLS; TH2 CELLS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029995816     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (214)

1. Devesa, S. S. and Fears, T., Non-Hodgkin's lymphoma time trends: United States and international data, Cancer Res., Suppl. 19, 5432s, 1992.
2. Levine, A. M., AIDS-related malignancies: the emerging epidemic, J. Natl. Cancer Inst., 85, 1382, 1993.
3. Beardsley, T., A war not won, Sci. Am., 270, 130, 1994.
4. Magrath, I., Molecular basis of lymphomagenesis, Cancer Res., 52, 5529s, 1992.
5. Drexler, H. G., MacLeod, R. A., Borkhardt, A., and Janssen, J. W., Recurrent chromosomal translocations and fusion genes in leukemia-lymphoma cell lines, Leukemia, 9, 480, 1995.
6. Rabbitts, T. H., Chromosomal translocations in human cancer, Nature, 372, 143, 1994.
7. Cline, M. J., The molecular basis of leukemia, N. Engl. J. Med., 330, 328, 1994.
8. Haynes, B. F. and Denning, S. M., Lymphopoiesis, in The Molecular Basis of Blood Diseases, Stamatoyannopoulos, G., Neinhuis, A., Majerus, P., and Varmus, H., Eds., 2nd ed., W. B. Saunders, Philadelphia, 1994, 425.
9. Grimaldi, J. C. and Meeker, T. C., The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene, Blood, 73, 2081, 1989.
10. Meeker, T. C., Hardy, D., Willman, C., Hogan, T., and Abrams, J., Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia, Blood, 76, 285, 1990.
11. Chang, J. M., Metcalf, D., Lang, R. A., Gonda, T. J., and Johnson, G. R., Nonneoplastic hematopoietic myeloproliferative syndrome induced by dysregulated multi-CSF (IL-3) expression, Blood, 73, 1487, 1989.
12. Chen, S. J., Holbrook, N. J., Mitchell, K. F., Vallone, C. A., Greengard, J. S., Crabtree, G. R., and Lin, Y., A viral long terminal repeat in the interleukin 2 gene of a cell line that constitutively produces interleukin 2, Proc. Natl. Acad. Sci. U.S.A., 82, 7284, 1985.
13. Tohyama, K., Lee, K. H., Tashiro, K., Kinashi, T., and Honjo, T., Establishment of an interleukin-5-dependent subclone from an interleukin-3-dependent murine hemopoietic progenitor cell line, LyD9, and its malignant transformation by autocrine secretion of interleukin-5, EMBO J., 9, 1823, 1990.
14. Blankenstein, T., Qin, Z., Li, W., and Diamantstein, T., DNA rearrangement and constitutive expression of the interleukin 6 gene in a mouse plasmacytoma, J. Exp. Med., 171, 965, 1990.
15. Baker, A. H., Cachia, P. G., Ridge, S., McGlynn, H., Clarke, R., Whittaker, J. A., Jacobs, A., and Padua, R. A., FMS mutations in patients following cytotoxic therapy for lymphoma, Leuk. Res., 19, 309, 1995.
16. Baker, A. H., Cachia, P. G., Tennant, G. B., Whittaker, J. A., White, D., Stanley, E. R., Burnett, A. K., and Padua, R. A., A novel CSF-1 binding factor in a patient in complete remission following cytotoxic therapy for lymphoma, Br. J. Haematol., 89. 219, 1995.
17. Taylor, C., McGlynn, H., Carter, G., Baker, A. H., Warren, N., Ridge, S. A., Owen, G., Thompson, E., Thompson, P. W., Jacobs, A. et al., RAS and FMS mutations following cytotoxic therapy for childhood acute lymphoblastic leukaemia, Leukemia, 9, 466, 1995.
18. Kadin, M. E., Cavaille-Coll, M. W., Gertz, R., Massague, J., Cheifetz, S., and George, D., Loss of receptors for transforming growth factor beta in human T-cell malignancies, Proc. Natl. Acad. Sci. U.S.A., 91, 6002, 1994.
19. Kono, T., Doi, T., Yamada, G., Hatakeyama, M., Minamoto, S., Tsudo, M., Miyasaka, M., Mitaya, T., and Taniguchi, T., Murine interleukin 2 receptor β chain: dysregulated gene expression in lymphoma line EL-4 caused by promoter insertion, Proc. Natl. Acad. Sci. U.S.A., 87, 1806, 1990.
20. Barker, C. S., Bear, S. E., Keler, T., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Yeung, R. S., and Tsichlis, P. N., Activation of the prolactin receptor gene by promoter insertion in a Moloney murine leukemia virus-induced rat thymoma, J. Virol, 66, 6763, 1992.
21. Ellisen, L. W., Bird, J., West, D. C., Soreng, A. L., Reynolds, T. C., Smith, S. D., and Sklar, J., TAN 1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms, Cell, 66, 649, 1991.
22. Jhappan, C., Callahan, D., Stahle, C., Chu, E., Smith, G. H., Merlino, G., and Callahan R., Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands, Genes Dev., 6, 345, 1992.
23. Robbins, J., Blondel, B. J., Gallahan, D., and Callahan, R., Mouse mammary tumor gene int-3: a member of the notch gene family transforms mammary epithelial cells. J. Virol., 66, 2594, 1992.
24. Larsson, C., Lardelli, M., White, I., and Lendahl, U., The human NOTCHI, 2, and 3 genes are located at chromosome positions 9q34, 1p13-p11, and 19p13.2-p 13.1 in regions of neoplasia-associated translocation, Genomics, 24, 253, 1994.
25. Swiatek, P. J., Lindsell, C. E., del Amo, F. F., Weinmaster, G., and Gridley, T., Notch1 is essential for postimplantation development in mice, Genes Dev., 8, 707, 1994.
26. Milner, L. A., Kopan, R., Martin, D. I., and Bernstein, I. D., A human homologue of the Drosophila developmental gene, Notch, is expressed in CD34+ hematopoietic precursors, Blood, 83, 2057, 1994.
27. Lindsell, C. E., Shawber, C. J., Boulter, J., and Weinmaster, G., Jagged: a mammalian ligand that activates Notch1, Cell, 80, 909, 1995.
28. Brickell, P. M., The p60c-src family of protein tyrosine kinases: structure, regulation, and function, Crit. Rev. Oncogen., 3, 401, 1992.
29. Voronova, A. F. and Sefton, B. M., Expression of a new tyrosine protein kinase is stimulated by retrovirus promoter insertion, Nature, 319, 682, 1986.
30. Shin, S. and Steffen, D. L., Frequent activation of the lck gene by promoter insertion and aberrant splicing in murine leukemia virus-induced rat lymphomas, Oncogene, 8, 141, 1993.
31. Tycko, B., Smith, S. D., and Sklar, J., Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia, J. Exp. Med., 174, 867, 1991.
32. Abraham, K. M., Levin, S. D., Marth, J. D., Forbush, K. A., and Perlmutter, R. M., Thymic tumorigenesis induced by overexpression of p561ck, Proc. Natl. Acad. Sci. U.S.A., 88, 3977, 1991.
33. Burnett, R. C., Thirman, M. J., Rowley, J. D., and Diaz, M. O., Molecular analysis of the T-cell acute lymphoblastic leukemia-associated t(1;7)(p34;q34) that fuses LCK and TCRβ, Blood, 84, 1232, 1994.
34. Wright, D. D., Seton, B. M., and Kamps, M. P., Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia, Mol. Cell Biol., 14, 2429, 1994.
35. Witte, O. N., Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture, Cancer Res., 53, 485, 1993.
36. Westbrook, C. A., Hooberman, A. L., Spino, C., Dodge, R. K., Larson, R. A., Davey, F., Wurster-Hill, D. H., Sobol, R. E., Schiller, C., and Bloomfield, C. D., Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762), Blood, 80, 2983, 1992.
37. Radich, J. P., Kopecky, K. J., Boldt, D. H., Head, D., Slovak, M. L., Babu, R., Kirk, J., Lee, A., and Kessler, P., Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction, Leukemia, 8, 1688, 1994.
38. Devaraj, P. E., Foroni, L., Kitra-Roussos, V., and Seeker-Walker, L. M., Detection of BCR-ABL and E2A-PBX1 fusion genes by RT-PCR in acute lymphoblastic leukaemia with failed or normal cytogenetics, Br. J. Haematol., 89, 349, 1995.
39. van Rhee, F., Marks, D. I., Lin, F., Szydlo, R. M., Hochhaus, A., Treleaven, J., Delord, C., Cross, N. C., and Goldman, J. M., Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow, Leukemia, 9, 329, 1995.
40. Clark, S. S., McLaughlin, J., Crist, W. M., Champlin, R., and Witte, O. N., Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL, Science, 235, 85, 1987.
41. Hermans, A., Heisterkamp, N., von Linden, M., van Baal, S., Meijer, D., van der Plas, D., Wiedemann, L. M., Groffen, J., Bootsma, D., and Grosveld, G., Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia, Cell, 51, 33, 1987.
42. McLaughlin, J., Chianese, E., and Witte, O. N., Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells, Mol. Cell Biol., 9, 1866, 1989.
43. Lugo, T. G., Pendergast, A. M., Muller, A. J., and Witte, O. N., Tyrosine kinase activity and transformation potency of bcr-abl oncogene products, Science, 247, 1079, 1990.
44. Hariharan, I. K., Harris, A. W., Crawford, M., Abud, H., Webb, E., Cory, S., and Adams, J. M., A bcr-v-abl oncogene induces lymphomas in transgenic mice, Mol. Cell. Biol., 9, 2798, 1989.
45. Clark, S. S., Chen, E., Fizzotti, M., Witte, O. N., and Malkovska, V., BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets, J. Virol., 67, 6033, 1993.
46. Afar, D. E., Goga, A., McLaughlin, J., Witte, O. N., and Sawyers, C. L., Differential complementation of Bcr-Abl point mutants with c-Myc, Science, 264, 424, 1994.
47. Cleary, M. L., Transcription factors in human leukemias, Cancer Surv., 15, 89, 1992.
48. Spencer, C. A. and Groudine, M., Control of c-myc regulation in normal and neoplastic cells, Adv. Cancer Res., 56, 1, 1990.
49. Marcu, K., Bossone, S., and Patel, A., myc function and regulation, Annu. Rev. Biochem., 61, 809, 1992.
50. Västrik, I., Mäkelä, T. P., Koskinen, P. J., Klefstrom, J., and Alitaro, K., Myc protein: partners and antagonists, Crit. Rev. Oncogen., 5, 59, 1994.
51. Benvenisty, N., Leder, A., Kuo, A., and Leder, P., An embryonically expressed gene is a target for c-Myc regulation via the c-Myc-binding sequence, Genes Dev., 6, 2513, 1992.
52. Yang, B.-S., Gilbert, J. D., and Freytag, S. O., Overexpression of Myc suppresses CCAAT transcription factor-nuclear factor 1-dependent promoters in vivo, Mol. Cell. Bio., 13, 3093, 1993.
53. Gaubatz, S., Meichle, A., and Eilers, M., An E-box element localized in the first intron mediates regulation of the prothymosin α gene by c-myc, Mol. Cell. Biol., 14, 3853, 1994.
54. Philipp, A., Schneider, A., Väsrik, I., Finke, K., Xiong, Y., Beach, D., Alitalo, K., and Eilers, M., Repression of cyclin D1: a novel function of Myc, Mol. Cell Biol., 14, 4032, 1994.
55. Daksis, J. I., Lu, R. Y., Facchini, L. M., Marhin, W. W., and Penn, L. J. Z., Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle, Oncogene, 9, 3635, 1994.
56. Rezanka, L., Rojko, J., and Neil, J. C., Feline leukemia virus: pathogenesis of neoplastic disease, Cancer Invest., 10, 371, 1992.
57. Levy, L. S., Lobelle-Rich, P., Overbaugh, J., Abkowitz, J., Fulton, R., and Roy-Burman, P., Coincident involvement of flvi-2, c-myc, and novel env genes in natural and experimental lymphosarcomas induced by feline leukemia virus, Virology, 196, 892, 1993.
58. Tsatsanis, C., Fulton, R., Tsujimoto, H., Levy, L. S., Terry, A., Onions, D., and Neil, J. C., Genetic determinants of feline leukemia virus-induced lymphoid tumors: patterns of proviral insertion and gene rearrangement, J. Virol., 68, 8296, 1994.
59. Levy, L. S., Gardner, M. B., and Casey, J. W., Isolation of a feline leukemia provirus containing the oncogene myc from a feline lymphosarcoma, Nature, 308, 853, 1984.
60. Bonham, L., Lobelle-Rich, P. A., Henderson, L. A., and Levy, L. S., Transforming potential of a myccontaining variant of feline leukemia virus in vitro in early-passage feline cells, J. Virol., 61, 3072, 1987.
61. Levy, L. S., Fish, R. E., and Baskin, G., Tumorigenic potential of a myc-containing strain of feline leukemia virus in vivo in domestic cats, J. Virol., 62, 4770, 1988.
62. Levy, L. S. and Lobelle-Rich, P. A., Insertional mutagenesis of flvi-2 in tumors induced by infection with LC-FeLV, a myc-containing strain of feline leukemia virus, J. Virol., 66, 2885, 1992.
63. Levy, L. S., Lobelle-Rich, P. A., and Overbaugh, J., flvi-2, a target of retroviral insertional mutagenesis in feline thymic lymphosarcomas, encodes bmi-1, Oncogene, 8, 1833, 1993.
64. Haupt, Y., Alexander, W., Barri, G., Klinken, S., and Adams, J. M., Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eμ-myc transgenic mice, Cell, 65, 753, 1991.
65. van Lohuizen, M., Verbeek, S., Scheijen, B., Wientjens, E., van der Gulden, H., and Berns, A., Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging, Cell, 65, 737, 1991.
66. Brown, L., Cheng, J. T., Chen, Q., Siciliano, M. J., Crist, W., Buchanan, G., and Baer, R., Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia, EMBO J., 9, 3343, 1990.
67. Aplan, P. D., Lombardi, D. P., Ginsberg, A. M., Cossman, J., Bertness, V. L., and Kirsch, I. R., Disruption of the human SCL locus by illegitimate V-(D)-J recombinase activity, Science, 250, 1426, 1990.
68. Begley, C. G., Aplan, P. D., Denning, S. M., Haynes, B. F., Waldmann, T. A., and Kirsch, I. R., The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif, Proc. Natl. Acad. Sci. U.S.A., 86, 10128, 1989.
69. Hsu, H. L., Huang, L., Tsan, J. T., Funk, W., Wright, W. E., Hu, J. S., Kingston, R. E., and Baer, R., Preferred sequences for DNA recognition by the TALI helix-loop-helix proteins, Mol. Cell. Biol., 14, 1256, 1994.
70. Hsu, H. L., Wadman, I., Tsan, J. T., and Baer, R., Positive and negative transcriptional control by the TAL1 helix-loop-helix protein, Proc. Natl. Acad. Sci. U.S.A., 91, 5947, 1994.
71. Goldfarb, A. N. and Lewandowska, K., Inhibition of cellular differentiation by the SCL/tal oncoprotein: transcriptional repression by an Id-like mechanism, Blood, 85, 465, 1995.
72. Xia, Y., Brown, L., Yang, C. Y., Tsan, J. T., Siciliano, M. J., Espinosa, R., III, Le Beau, M. M., and Baer, R. J., TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia, Proc. Natl. Acad. Sci. U.S.A., 88, 11416, 1991.
73. Cleary, M. L., Mellentin, J. D., Spies, J., and Smith, S. D., Chromosomal translocation involving the beta T cell receptor gene in acute leukemia, J. Exp. Med., 167, 682, 1988.
74. Xia, Y., Hwang, L. Y., Cobb, M. H., and Baer, R., Products of the TAL2 oncogene hi leukemic T cells: bHLH phosphoproteins with DNA-binding activity, Oncogene, 9, 1437, 1994.
75. Kennedy, M. A., Gonzalez-Sarmiento, R., Kees, U. R., Lampert, F., Dear, N., Boehm, T., and Rabbitts, T. H., HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24, Proc. Natl. Acad. Sci. U.S.A., 88, 8900, 1991.
76. Hawley, R. G., Fong, A. Z., Lu, M., and Hawley, T. S., The HOX11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors, Oncogene, 9, 1, 1994.
77. Roberts, C. W., Shutter, J. R., and Korsmeyer, S. J., Hox 11 controls the genesis of the spleen, Nature, 368, 747, 1994.
78. Nourse, J., Mellentin, J. D., Galili, N., Wilkinson, J., Stanbridge, E., Smith, S. D., and Cleary, M. L., Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor, Cell. 60, 535, 1990.
79. Hunger, S. P., Galili, N., Carroll, A. J., Crist, W. M., Long, M. P., and Cleary, M. L., The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias, Blood, 77, 687, 1991.
80. Numata, S., Kato, K., and Horibe, K., New E2A/ PBX1 fusion transcript in a patient with t(1;19)(q23;p13) acute lymphoblastic leukemia, Leukemia, 7, 1441, 1993.
81. Privitera, E., Luciano, A., Ronchetti, D., Arico, M., Santostasi, T., Basso, G., and Biondi, A., Molecular variants of the 1;19 chromosomal translocation in pediatric acute lymphoblastic leukemia (ALL), Leukemia, 8, 554, 1994.
82. Kamps, M. P. and Baltimore, D., E2A-Pbx1, the t(1;19) translocation protein of human pre-B-cell acute lymphocytic leukemia, causes acute myeloid leukemia in mice, Mol. Cell Biol., 13, 351, 1993.
83. Lu, Q., Wright, D. D., and Kamps, M. P., Fusion with E2A converts the Pbx1 homeodomain protein into a constitutive transcriptional activator in human leukemias carrying the t(1;19) translocation. Mol. Cell Biol., 14, 3938, 1994.
84. McGuire, E. A., Hockett, R. D., Pollock, K. M., Bartholdi, M. F., O'Brien, S. J., and Korsmeyer, S. J., The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-1, a gene encoding a potential zinc finger protein, Mol. Cell Biol., 9, 2124, 1989.
85. Sanchez-Garcia, I. and Rabbitts, T. H., The LIM domain: a new structural motif found in zinc-finger-like proteins, Trends Genet., 10, 315, 1994.
86. Royer-Pokora, B., Rogers, M., Zhu, T. H., Schneider, S., Loos, U., and Bolitz, U., The TTG-2/ RBTN2 T cell oncogene encodes two alternative transcripts from two promoters: the distal promoter is removed by most 11p13 translocations in acute T cell leukaemia's (T-ALL), Oncogene, 10, 1353, 1995.
87. McGuire, E. A., Rintoul, C. E., Sclar, G. M., and Korsmeyer, S. J., Thymic overexpression of Ttg-1 in transgenic mice results in T-cell acute lymphoblastic leukemia/lymphoma, Mol. Cell Biol., 12, 4186, 1992.
88. Valge-Archer, V. E., Osada, H., Warren, A. J., Forster, A., Li, J., Baer, R., and Rabbitts, T. H., The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells, Proc. Natl. Acad. Sci. U.S.A., 91, 8617, 1994.
89. Neri, A., Chang, C. C., Lombardi, L., Salina, M., Corradini, P., Maiolo, A. T., Chaganti, R. S., and Dalla-Favera, R., B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50, Cell, 67, 1075, 1991.
90. Fracchiolla, N. S., Lombardi, L., Salina, M., Migliazza, A., Baldini, L., Berti, E., Cro, L., Polli, E., Maiolo, A. T., and Neri, A., Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies, Oncogene, 8, 2839, 1993.
91. Thakur, S., Lin, H. C., Tseng, W. T., Kumar, S., Bravo, R., Foss, F., Gélinas, C., and Rabson, A. B., Rearrangement and altered expression of the NFkB2 gene in human cutaneous T-lymphoma cells, Oncogene, 9, 2335, 1994.
92. Zhang, J, Chang, C. C., Lombardi, L., and Dalla-Favera, R., Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions, Oncogene, 9, 1931, 1994.
93. Lanoix, J., Lacoste, J., Pepin, N., Rice, N., and Hiscott, J., Overproduction of NFKB2 (lyt-10) and c-Rel: a mechanism for HTLV-I Tax-mediated transactivation via the NF-kappa B signaling pathway, Oncogene, 9, 841, 1994.
94. Ohno, H., Takimoto, G., and McKeithan, T. W., The candidate protooncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control, Cell, 60, 991, 1990.
95. Ohno, H., Doi, S., Yabumoto, K., Fukuhara, S., and McKeithan, T. W., Molecular characterization of the t(14;19)(q32;q13) translocation in chronic lymphocytic leukemia, Leukemia, 7, 2057, 1993.
96. Zhang, Q., Didonato, J. A., Karin, M., and McKeithan, T. W., BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins, Mol. Cell Biol., 14, 3915, 1994.
97. Rubnitz, J. E., Link, M. P., Shuster, J. J., Carroll, A. J., Hakami, N., Frankel, L. S., Pullen, D. J., and Cleary, M. L., Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a pediatric oncology group study, Blood, 84, 570, 1994.
98. Cimino, G., Rapanotti, M. C., Rivolta, A., Lo Coco, F., D'Arcangelo, E., Rondelli, R., Basso, G., Barisone, E., Rosanda, C., Santostasi, T., et al., Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias, Leukemia, 9, 391, 1995.
99. Ford, A. M., Ridge, S. A., Cabrera, M. E., Mahmoud, H., Steel, C. M., Chan, L. C., and Greaves, M., In utero rearrangements in the trithorax-related oncogene in infant leukaemias, Nature, 363, 358, 1993.
100. Stock, W., Thirman, M. J., Dodge, R. K., Rowley, J. D., Diaz, M. O., Wurster-Hill, D., Sobol, R. E., Davey, F. R., Larson, R. A., Westbrook, C. A et al., Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia, Leukemia, 8, 1918, 1994.
101. Domer, P. H., Fakharzadeh, S. S., Chen, C. S., Jockel, J., Johansen, L., Silverman, G. A., Kersey, J. H., and Korsmeyer, S., Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product, Proc. Natl. Acad. Sci. U.S.A., 90, 7884, 1993.
102. Schichman, S. A., Canaani, E., and Croce, C. M., Self-fusion of the ALL1 gene, JAMA, 273, 571, 1995.
103. Thirman, M. J., Gill, H. J., Burnett, R. C., Mbangkollo, D., McCabe, N. R., Kobayashi, H., Ziemin-van der Poel, S., Kaneko, Y., Morgan, R. et al., Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations, N. Engl. J. Med., 329, 909, 1993.
104. Chen, C. S., Sorensen, P. H., Domer, P. H., Reaman, G. H., Korsmeyer, S. J., Heerema, N. A., Hammond, G. D., and Kersey, J. H., Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome, Blood, 81, 2386, 1993.
105. Repp, R., Borkhardt, A., Haupt, E., Kreuder, J., Brettreich, S., Hammermann, J., Nishida, K., Harbott, J., and Lampert, F., Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis, Leukemia, 9, 210, 1995.
106. Starkey, C. and Levy, L. S., Identification of differentially expressed genes in T-lymphoid malignancies in an animal model system, Int. J. Cancer, in press, 1995.
107. Riis, B., Rattan, S. I., Clark, B. F., and Merrick, W. C., Eukaryotic protein elongation factors, Trends Biochem. Sci., 15, 420, 1990.
108. Shepherd, J. C. W., Walldorf, U., Hug, P., and Gehring, W. J., Fruit flies with additional expression of the elongation factor EF-1α live longer, Proc. Natl. Acad. Sci. U.S.A., 86, 7520, 1989.
109. Tatsuka, M., Mitsui, H., Wada, M., Nagata, A., Nojima, H., and Okayama, H., Elongation factor-1α gene determines susceptibility to transformation, Nature, 359, 333, 1992.
110. Adams, S. M., Sharp, M. G. F., Walker, R. A., Brammar, W. J., and Varley, J. M., Differential expression of translation-associated genes in benign and malignant human breast tumours, Br. J. Cancer, 65, 65, 1992.
111. Grant, A. G., Flomen, R. M., Tizard, M. L. V., and Grant, D. A. W., Differential screening of a human pancreatic adenocarcinoma λgt11 expression library has identified increased transcription of elongation factor EF-1α in tumour cells, Int. J. Cancer, 51, 740, 1992.
112. Wool, I. G., The bifunctional nature of ribosomal proteins and speculations on their origins, in The Translational Apparatus, Plenum Press, New York, 1993, 727.
113. Korsmeyer, S. J., Regulators of cell death, Trends Genet., 11, 101, 1995.
114. Kamb, A., Cell-cycle regulators and cancer, Trends Genet., 11, 136, 1995.
115. Delmer, A., Ajchenbaum-Cymbalista, F., Tang, R., Ramond, S., Faussat, A. M., Marie, J. P., and Zittoun, R., Overexpression of cyclin D2 in chronic B-cell malignancies, Blood, 85, 2870, 1995.
116. Harris, A. W., Bodrug, S. E., Warner, B. J., Bath, M. L., Lindeman, G. J., and Adams, J. M., Cyclin D1 as the putative bcl-1 oncogene, Curr. Top. Microbiol. Immunol, 194, 347, 1995.
117. de Boer, C. J., van Krieken, J. H., Kluin-Nelemans, H. C., Kluin, P. M., and Schuuring, E., Cyclin D1 messenger RNA Overexpression as a marker for mantle cell lymphoma, Oncogene, 10, 1833, 1995.
118. Stranks, G., Height, S. E., Mitchell, P., Jadayel, D., Yuille, M. A., De Lord, .C., Clutterbuck, R. D., Treleaven, J. G., Powles, R. L., Nacheva, E. et al., Deletions and rearrangement of CDKN2 in lymphoid malignancy, Blood, 85, 893, 1995.
119. Hawkins, C. J. and Vaux, D. L., Analysis of the role of bcl-2 in apoptosis, Immunol. Rev., 142, 127, 1994.
120. de Jong, D., Prins, F. A., Mason, F. A., Reed, J. C., van Ommen, G. B., and Kluin, P. M., Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells, Cancer Res., 54, 256, 1994.
121. Lane, D. P., p53 and human cancers, Br. Med. Bull., 50, 582, 1994.
122. Cheng, J. and Haas, M., Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines, Mol. Cell. Biol., 10, 5502, 1990.
123. Yeargin, J., Cheng, J., Yu, A. L., Gjerset, R., Bogart, M., and Haas, M., P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines, J. Clin. Invest., 91, 2111, 1993.
124. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M., and Dalla-Favera, R., p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. U.S.A., 88, 5413, 1991.
125. Hsiao, M. H., Yu, A. L., Yeargin, J., Ku, D., and Haas, M., Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase, Blood, 83, 2922, 1994.
126. Hsiao, M., Low, J., Dorn, E., Ku, D., Pattengale, P., Yeargin, J., and Haas, M., Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness, Am. J. PathoL, 145, 702, 1994.
127. Pui, C.-H., Childhood leukemias, N. Engl. J. Med., 332, 1618, 1995.
128. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horn, Y., Iwato, K., Asoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A., and Kishimoto, T., Autocrine generation and requirement of BSF-2/IL-6 for multiple myelomas, Nature (London), 332, 83, 1988.
129. Freeman, G. J., Freedman, A. S., Rabinowe, S. N., Segil, J. M., Horowitz, J., Rosen, K., Whitman, J. F., and Nadler, L. M., Interleukin 6 gene expression in normal and neoplastic B cells, J. Clin. Invest., 83, 1512, 1989.
130. Biondi, A., Rossi, V., Bassan, R., Bettoni, T., Sirono, S., Mantovani, M., and Rambaldi, A., Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood, 73, 1279, 1989.
131. Tosato, G., Tanner, J., Jones, K. D., Revel, M., and Pike, S. E., Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus immortalized B cells, J. Virol., 64, 3033, 1990.
132. Swada, T., Tsuda, H., and Takatsuki, K., Spontaneous production of interleukin-6 by adult T cell leukemia cells, Br. J. Cancer, 62, 923, 1990.
133. Yokoi, T., Miyawaki, T., Yachie, A., Kato, K., Kasahara, Y., and Taniguchi, N., Epstein-Barr virus immortalized B cells produce IL-6 as an autocrine growth factor, Immunology, 70, 100, 1990.
134. Vink, A., Coulie, P., Warnier, G., Renauld, J. C., Stevens, M., Donckers, D., and Van Snick, J., Mouse plasmacytomas growth in vivo: Enhancement by IL-6 and inhibition by antibodies directed against IL-6 or its receptor, J. Exp. Med., 172, 997, 1990.
135. Merz, H., Fliedner, A., Orscheschek, K., Binder, T., Sebald, W., Muller-Hermelink, H. K., and Feller, A. C., Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth, Am. J. Pathol, 139, 1173, 1991.
136. Hsu, S-M., Xie, S. S., and Waldron, J. A., Functional heterogeneity and pathogenic significance of interleukin-6 in B-cell lymphomas, Am. J. Pathol., 141, 915, 1992.
137. Hata, H., Xiao, H., Petrucci, T., Woodliff, J., Chang, R., and Epstein, J., Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells, Blood, 81, 3357, 1993.
138. Hsu, S-M., Waldron, J. M., Fink, L., King, C., Xie, S. S., Mansouri, A., and Barlogie, B., Pathogenic significance of interleukin-6 in Angioimmunoblastic lymphadenopathy type T cell lymphoma, Hum. Pathol., 24, 126, 1993.
139. Bost, K. L., Bieligk, S. C., and Jaffe, B. M., Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies: tumor-derived IL-10 as a possible mechanism for affecting the anti-tumor response, J. Immunol., 154, 718, 1995.
140. Klein, B., Zhang, X.-G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., and Bataille, R., Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6, Blood, 73, 517, 1989.
141. Emlie, D., Devergne, O., Raphael, M., Coumvaras, L. J., and Galanaud, P., Production of interleukin-6 in high-grade B lymphomas, Curr. Top. Microbiol. Immunol., 182, 349, 1992.
142. Foss, H. D., Anafnostopoulos, I., Herbst, H., Greve, M., Ziemann, K., Hummel, H., and Stein, H., Patterns of cytokine gene expression in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type, Blood, 85, 2862, 1995.
143. Calligaris-Cappio, F., Bergui, L., Gregoretti, M. G., Gaidano, G., Gabolli, M., Schena, M., Zallone, A. Z., and Marchisio, P. C., Role of bone marrow stromal cells in the growth of human multiple myeloma, Blood, 77, 2688, 1991.
144. Du Villare, L., Guiguet, M., Casanovas, R. O., Caillot, D., Monnier-Zeller, V., Bernard, A., Guy, H., and Solary, E., Diagnostic value of serum IL-6 level in monoclonal gammopathies, Br. J. Haematol., 89, 243, 1995.
145. Pelliniemi, T. T., Irjala, K., Mattila, K., Pulkki, K., Rajamaki, A., Tienhaara, A., Laakso, M., and Lahtinen, R., Immunoreactive IL-6 and acute phase proteins as prognostic factors in multiple myeloma, Blood, 85, 765, 1995.
146. Bataille, R., Barlogie, B., Lu, Z. Y., Rossi, J., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., and Klein, B., Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma, Blood, 86, 685, 1995.
147. Namen, A. E., Lupton, S., Kjerrild, K., Wignall, J., Mochizuki, D. Y., Schmierer, A., Mosley, B., March, C. J., Urdal, D., Gillis, S., Cosman, D., and Goodwin, R. G., Stimulation of B cell progenitors by cloned murine IL-7, Nature, 333, 571, 1988.
148. Goodwin, R. G., Lupton, S., Schmierer, A., Hjerrild, K. J., Jerzy, R., Clevenger, W., Gillis, S., Cosman, D., and Namen, A. E., Human interleukin-7: Molecular cloning and growth factor activity on human and murine B lineage cells, Proc. Natl. Acad. Sci. U.S.A., 86, 302, 1989.
149. Morrissey, P. J., Goodwin, R. G., Nordan, R. P., Anderson, D., Grabstein, K. H., Cosman, D., Sims, J., Lupton, S., Acres, B., Reed, S. G., Mochizuki, D., Eisenman, J., Conlon, P. J., and Namen, A. E., Recombinant interleukin-7, pre-B-cell growth factor, has costimulatory activity on purified mature T cells, J. Exp. Med., 169, 707, 1989.
150. Digel, W., Schmid, M., Heil, G., Conrad, P., Gillis, S., and Porzsolt, F., Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias, Blood, 78, 753, 1991.
151. Yoshioka, R., Schimizu, S., Tachibana, J., Hirose, Y., Fukutoku, M., Takeuchi, Y., Sugai, S., Takiguchi, T., and Konda, S., Interleukin-7-induced proliferation of CD8+ T chronic lymphocytic leukemia cells, J. Clin. Immunol., 12, 101, 1992.
152. Dalloul, A., Laroche, L., Bagot, M., Mossalayi, M. D., Fourcade, C., Thacker, D. J., Hogge, D. E., Herle-Beral, H., Debre, P., and Schmitt, C., Interleukin-7 is a growth factor for Sezary lymphoma cells, J. Clin. Invest., 90, 1054, 1992.
153. Foss, F. M., Koc, Y., Stetler-Stevenson, M. A., Nguyen, D. T., O'Brien, M. C., Turner, R., and Sausville, E. A., Costimulation of cutaneous T cell lymphoma cells by interleukin 7 and interleukin 2: potential autocrine or paracrine effectors in the Sezary syndrome, J. Clin. Oncol., 12, 326, 1994.
154. Frishman, J., Long, B., Knopse, W., Gregory, S., and Plate, J., Genes for IL-7 are transcribed in leukemic cell subsets of individuals with chronic lymphatic leukemia, J. Exp. Med., 177, 955, 1993.
155. Benjamin, D., Sharma, V., Knobloch, T. J., Armitage, R. J., Dayton, M. A., and Goodwin, R. G., B cell IL-7: human B cell lines constitutively secrete IL-7 and express IL-7 receptors, J. Immunol., 152, 4749, 1994.
156. Rich, B. E., Campos-Torres, J., Tepper, R. I., Moreadith, R. W., and Leder, P., Cutaneous lymphoproliferation and lymphomas in IL-7 transgenic mice, J. Exp. Med., 177, 305, 1993.
157. Renauld, J. C., Houssiau, F., Louahed, J., Vink, A., Van Snick, J., and Uyttenhove, C., Interleukin 9, Adv. Immunol., 54, 79, 1993.
158. Vink, A., Renauld, J. C., Warnier, B. and Van Snick, J., Interleukin-9 stimulates in vitro growth of mouse thymic lymphomas., Eur. J. Immunol., 23, 1134, 1993.
159. Houssiau, F., Renauld, J. C., Stevens, M., Lehmann, F., Coulie, P. G., and Van Snick, J., Human T cell lines and clones respond to IL-9, J. Immunol., 150, 2634, 1993.
160. Renauld, J. C., Vink, A., Louahed, J., and Van Snick, J., Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas, Blood, 85, 1300, 1995.
161. Merz, H., Houssiau, F. A., Orscheschek, K., Renauld, J. C., Fliedner, A., Herin, M., Noel, H., Kadin, M., Mueller-Hermelink, H. K., and Van Snick, J., IL-9 expression in human malignant lymphomas, Blood, 78, 1311, 1991.
162. Uyttenhove, C., Druez, C., Renauld, J. C., Herin, M., Noel, H., and Van Snick, J., Autonomous growth and tumorigenicity induced by P40/IL-9 cDNA transfection of a mouse P-40 dependent T cell line, J. Exp. Med., 173, 519, 1991.
163. Renauld, J. C., van der Lust, N. Vink, A., van Roon, M., Godfraind, C., Warmer, G., Merz, H., Feller, A., Berns, A., and Van Snick, J., Thymic lymphomas in interleukin 9 transgenic mice, Oncogene, 9, 1327, 1994.
164. Moore, K. W., O'Garra, A., Malefyt, R. W., Vieira, P., and Mosmann, T. R., Interleukin-10, Annu. Rev. Immunol., 11, 165, 1993.
165. Rousset, F., Garcia, E., Defrance, T., Peronne, C., Vezzio, N., Hsu, D., Kastelein, R., Moore, K. W., and Banchereau, T., Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes, Proc. Natl. Acad. Sci. U.S.A., 89, 1890, 1992.
166. O'Garra, A., Stapleton, G., Dhar, V., Pearce, M., Schumacher, J., Rugo, H., Barbis, D., Stall, A., Cupp, J., Moore, K., Vieira, P., Mossman, T., Whitmore, A., Arnold, L., Haughton, G., and Howard, M., Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10, Int. Immunol., 2, 821, 1990.
167. Benjamin, D., Knobloch, T. J., and Dayton, M. A., Human B cell interleukin-10. B cell lines derived from patients with acquired immunodeficiency syndrone and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10, Blood, 80, 1289, 1992.
168. Burdin, N., Peronne, C., Banchereau, J., and Rousset, F., Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10, J. Exp. Med., 177, 295, 1993.
169. Masood, R., Zhang, Y., Bond, M. W., Scadden, D. T., Moudgil, T., Law, R. E., Kaplan, M. H., Jung, B., Espina, B. M., Lunardi-Iskandar, Y., Levine, A. M., and Gil, P. S., Interleukin-10 is an autocrine growth factor for acquired immuodeficiency syndrone-related B-cell lymphoma, Blood, 85, 3423, 1995.
170. Blay, J. Y., Burdin, N., Rousset, F., Lenoir, G., Biron, P., Philip, T., Banchereau, J., and Favrot, M. C., Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor, Blood, 82, 2169, 1993.
171. Stasi, R., Zinzani, P. L., Galieni, P., Lauta, V. M., Damasio, E., Dispensa, E., Dammacco, F., Tura, S., and Papa, G., Detection of soluble IL-2 receptor and IL-10 in the serum of patients with aggressive non-Hodgkin's lymphoma, Cancer, 74, 1792, 1994.
172. Cortes, J. E., Talpaz, M., Cabanillas, F., Seymour, J. F., and Kurzrock, R., Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis, Blood, 85, 2516, 1995.
173. Lu, Z. Y., Zhang, X. G., Rodriquez, C., Wijdenes, J., Gu, Z. J., Morel-Fournier, B., Harousseau, J. L., Bataille, R., Rossi, J. F., and Klein, B., Interleukin-10 is a proliferative factor but not a differentiation factor for human myeloma cells, Blood, 85, 2521, 1995.
174. Cordingley, F. T., Hoffvrand, A. V., Heslop, H. E., Turner, M., Bianchi, A., Feittie, J. E., Vykarnam, A., and Vrenner, M. K., Tumor necrosis factor as an autocrine growth factor for chronic B cell malignancies, Lancet, 1, 969, 1988.
175. Foa, R., Massaia, M., Cardona, S., Tyos, A. G., Bianchi, A., Attisano, C., Guarini, A., Di Celle, P. F., and Fierro, M. T., Production of tumor necrosis factor-alpha by B cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease, Blood, 76, 393, 1990.
176. Hahn, T., Kusminsky, G., Bassous, L., and Berrebi, A., Tumor necrosis factor production in B cell chronic lymphocytic leukemia, Leuk. Lymphoma, 4, 117, 1991.
177. Nilsson, K., Larsson, L. G., Soderverg, O., Schena, M., Gottardi, D., Caligaris-Cappio, F., and Carlsson, M., On the role of endogenously produced TNF-alpha and IL-6 as regulators of growth and differentiation of B-type chronic lymphocytic leukemia cells in vitro, Curr. Top. Microbiol. Immunol., 182, 271, 1992.
178. Lindemann, A., Ludwig, W. D., Oster, W., Mertelsmann, R., and Herrmann, F., High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia, Blood, 73, 880, 1989.
179. Sappino, A. P., Seelentag, W., Pelte, M. F., Alberto, P., and Vassalli, P., Tumor necrosis factor/cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients, Blood, 75, 958, 1990.
180. Weiss, C., Stehle, B., Ho, A. D., and Hunstein, W., Serum levels of tumor necrosis factor-alpha in hairy cell leukemia, Blood, 75, 321, 1990.
181. Ruco, L. P., Pomponi, D., Pigott, R., Stoppacciaro, A., Monardo, F., Uccini, S., Boraschi, D., Tagliabue, A., Santoni, Al, Dejana, E., Mantovani, A., and Baroni, C. D., Cytokine production and endothelial cell activation in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas, Am. J. Pathol., 137, 1163, 1990.
182. Digel, W., Stefanic, M., Schoniger, W., Buck, C., Raghavachar, A., Frickhofen, N., and Porzsolt, F., Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia, Blood, 73, 1242, 1989.
183. Digel, W., Schoniger, W., Stefanic, M., Janssen, H., Buck, C., Schmid, M., Raghavachar, A., and Porzsolt, F., Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo, Blood, 76, 1607, 1990.
184. Ryffel, B., Brockhaus, M., Durmuller, U., and Gudat, F., Tumor necrosis factor receptors in lymphoid tissues and lymphomas. Source and site of action of tumor necrosis factor alpha, Am. J. Pathol., 139, 7, 1991.
185. Heilig, B., Mapara, M., Brockhaus, M., Krauth, K., and Dorken, B., Two types of TNF receptors are expressed on human normal and malignant B lymphocytes, Clin. Immunol. Immunopathol., 61, 260, 1991.
186. Wahl, S. M., Transforming growth factor-beta: the good, the bad and the ugly, J. Exp. Med., 180, 1587, 1994.
187. McCartney-Francis, N. L. and Wahl, S. M., Transforming growth factor-beta: a matter of life and death, J. Leukocy. Biol., 55, 401, 1994.
188. Kremer, J. P., Reisbach, G., Nerl, C., and Dormer, P., B-cell chronic lymphocytic leukemia cells express and release transforming growth factor-beta, Br. J. Haematol., 80, 480, 1992.
189. Lotz, M., Ranheim, E., and Kipps, T. J., Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells, J. Exp. Med., 179, 99, 1994.
190. Lagneaux, L., Delforge, A., Dorval, C., Bron, D., and Stryckmans, P., Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and IL-6 production, Blood, 82, 2379, 1993.
191. Roth, C., Rochlitz, C., and Kourilsky, P., Immune response against tumors, Adv. Immunol., 57, 281, 1994.
192. Klein, E. and Mantovani, A., Action of natural killer cells and macrophages in cancer. Curr. Optn. Immunol., 5, 714, 1993.
193. Finn, O. J., Tumor rejection antigens recognized by T lymphocytes, Curr. Opin. Immunol., 5, 701, 1993.
194. Trinchieri, G., Biology of natural killer cells, Adv. Immunol., 47, 187, 1989.
195. Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S., and Ruco, L., The origin and function of tumor associated macrophages, Immunol. Today, 13, 265, 1992.
196. Topalian, S. L., MHC class II restricted tumor antigens and the role of CD4+ cells in cancer immunotherapy, Curr. Opin. Immunol., 6, 741, 1994.
197. Cherwinski, H. M., Schumacher, J. H., Brown, K. D., and Mosmann, T. R., Two types of mouse helper T cell clones, J. Exp. Med., 166, 1229, 1987.
198. Mosmann, T. R. and Coffman, R. L., TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, Ann. Rev. Immunol., 7, 145, 1989.
199. Arai, K. L., Miyajima, F., Miyatake, A., Arai, S., and Yokota, T., Cytokines: coordinators of immune and inflammatory responses, Ann. Rev. Biochem., 59, 783, 1990.
200. Hsieh, C. S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., and Murphy, K. M., Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages, Science, 260, 547, 1993.
201. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., and Trinchieri, G., Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes, J. Exp. Med., 170, 827, 1989.
202. Manetti, R., Gerosa, F., Giudizi, M. G., Biagiotti, R., Parronchi, P., Piccinni, M. P., Sampognaro, S., Maggi, E., Romagnani, S., and Trinchieri, G., IL-12 induces stable priming for interferon gamma production during differentiation of human T helper cells and transient interferon gamma production in established TH2 cell clones., J. Exp. Med., 179, 1273, 1994.
203. McKnight, A. J., Zimmer, G. J., Fogelman, I., Wolf, S. F., and Abbas, A. K., Effects of IL-12 on helper T-cell-dependent immune responses in vivo, J. Immunol., 152, 2172, 1994.
204. Seder, R. A., Gazzinelli, R., Sher, A., and Paul, W. E., IL-12 acts directly on CD4+ T cells to enhance priming for IFN-gamma production and diminishes IL-4 inhibition of such priming, Proc. Natl. Acad. Sci. U.S.A., 90, 10188, 1993.
205. Marshall, J. D., Secrist, H., Dekruyff, R. H., Wolf, S. F., and Umetsu, D. T., IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4+ T lymphocytes, J. Immunol., 155, 111, 1995.
206. Seder, R. A., Paul, Davis, M. M., and de St. Groth, B. F., The presence of IL-4 during in vitro priming determine the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice, J. Exp. Med., 176, 1091, 1992.
207. Hsieh, C. S., Heimberger A. B., Gold, J. S., O'Garra, A., and Murphy, K. M., Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system, Proc. Natl. Acad. Sci. U.S.A., 89, 6065, 1992.
208. McKenzie, A. N. J., Culpepper, J. A., de Waal Malefyt, R., Briere, F., Punnonen, J., Aversa, G., Sato, A., Dang, W., Cocks, B.G., Menon, S., de Vries, J. E., Banchereau, J., and Zurawski, G., Interleukin-13, a novel T-cell-derived cytokine that regulates monocyte and B cell function, Proc. Natl. Acad. Sci. U.S.A., 90, 3735, 1993.
209. Minty, A., Chalon, P., Derocq, J. M., Dumont, X., Guillemot, J. C., Kaghad, M., Labit, C., Leplatois, P., Liauzun, P., Miloux, B., Minty, C., Casellas, P., Loison, G., Lupker, J., Shire, D., Ferrera, P., and Caput, D., Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses, Nature, 362, 248, 1993.
210. Zurawski, G. and de Vries, J. E., Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells, Immunol. Today, 15, 1994.
211. Sulitzeanu, D., Immunosuppressive factors in human cancer, Adv. Cancer Res., 60, 247, 1993.
212. Armitage, R. J., Grabstein, K. H., and Alderson, M. R., Cytokine regulation of B-cell differentiation, in Cytokines and B Lymphocytes, Academic Press, San Diego. 1990, 115.
213. Akira, S., Taga, T., and Kishimoto, T., Interleukin-6 in biology and medicine, Adv. Immunol., 54, 1, 1993.
214. Berg, D. J. and Lynch, R. G., Immune dysfunction in mice with plasmacytomas, J. Immunol., 146, 2865, 1991.